About Clexane(R) / Lovenox(R)
The no. 1 selling low-molecular weight heparin in the world, Clexane(R) / Lovenox(R), is a unique chemical entity in a class of antithrombotic agents known as low-molecular weight heparins (LMWH).
Its clinical applications are linked to its antithrombotic properties. It is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or arterial thrombosis.
The recommended dose regimen of Clexane(R) in Japan is 20 mg b.i.d subcutaneous and has been established with the results of Japanese clinical trials.
Enoxaparin sodium is known by the brand name Lovenox(R) or Clexane(R) or Klexane(R) and its labelling may vary country to country.
About venous thromboembolism (VTE)
Venous thromboembolism is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein. This may occur in any part of the venous system, but the most common manifestations are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE). PE is a potentially life-threatening complication of DVT; anyone who experiences DVT is at risk of a PE, which occurs when part or all of a blood clot in a deep vein breaks away from where it originally formed and travels through the venous circulation, eventually becoming lodged in the lungs. This blocks the flow of blood in the lungs and is often fatal.
The total annual burden of non-fatal symptomatic VTE in the European
Union, which included DVT and PE, is estimated to exceed 1.5 million
events, including more than 500,000 deaths(3). This represents more than
Copyright©2008 PR Newswire.
All rights reserved